<DOC>
	<DOC>NCT00627926</DOC>
	<brief_summary>A Phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).</brief_summary>
	<brief_title>A Phase 3 Study of Telaprevir in Combination With Pegasys速 and Copegus速 in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Inclusion Criteria Has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C Male and female subjects, 18 to 70 years of age, inclusive Genotype 1, chronic hepatitis C with detectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Screening laboratory values, tests, and physical exam within acceptable ranges Able and willing to follow contraception requirements Able to read and understand, and willing to sign the informed consent form and abide by the study restrictions Exclusion Criteria Subject has any contraindications to Pegasys速 or Copegus速 therapy Evidence of hepatic decompensation in cirrhotic subjects History of organ transplant History of, or any current medical condition which could impact the safety of the subject in participation in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Genotype 1</keyword>
</DOC>